MétaCan
Menu
Back to cohort
Record W4414282985 · doi:10.51731/cjht.2025.1226

Abemaciclib (Verzenio)

2025· article· en· W4414282985 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsnot available
Fundersnot available
KeywordsMetastatic breast cancerBreast cancerDrugChemotherapyAromataseCancer

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Verzenio should be reimbursed by public drug plans for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer in patients who were postmenopausal in combination with nonsteroidal aromatase inhibitors (NSAIs) as an initial endocrine-based therapy, if certain conditions are met. Verzenio plus NSAI should be covered to treat adults with HR-positive, HER2-negative advanced or metastatic breast cancer, with a good performance status. Verzenio plus NSAI should not be covered in patients who have previously received cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors or received more than 1 line of chemotherapy for advanced or metastatic breast cancer. Verzenio plus NSAI should only be reimbursed if prescribed by clinicians with expertise in managing advanced or metastatic breast cancer and if the cost of Verzenio does not exceed the drug program cost of treatment with ribociclib plus NSAI, reimbursed for the indicated population.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.985
Threshold uncertainty score0.871

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.327
Teacher spread0.310 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207